The bill tightens outbound screening and expands authorities to protect U.S. biotech IP and supply chains, improving national security and domestic production readiness at the cost of reduced foreign investment, higher compliance burdens, potential chilling of legitimate research, and increased government control or opacity.
Researchers, biotech firms, and the public are less likely to see sensitive biotechnology IP, manufacturing know‑how, or clinical capabilities transferred to foreign adversaries, reducing risks to U.S. national security and supply‑chain exploitation.
Domestic vaccine, biologics, and biomanufacturing capacity can be strengthened through use of defense production authorities and prioritized investments, improving readiness and resilience of medical supply chains in crises.
Clearer rules on which biotech technologies and transaction types are sensitive — plus formal interagency coordination among Treasury, HHS, DoD, and intelligence officials — gives companies and investors better guidance for compliance and threat identification.
U.S. biotech companies and researchers may lose foreign investment and partnership opportunities, shrinking capital access and international collaboration.
New screening, notification, and licensing requirements will raise compliance costs and slow or complicate deals, potentially increasing transaction costs for firms and ultimately prices for consumers or taxpayers.
Broad restrictions and compliance uncertainty risk chilling legitimate international scientific collaboration and academic research, slowing drug development and harming global public‑health outcomes.
Based on analysis of 5 sections of legislative text.
Amends the Defense Production Act to treat core biotechnology transfers (licensing, joint ventures, equity) as subject to outbound screening and potential prohibition, and directs Treasury rulemaking and a DoD assessment.
Official title: To amend title VIII of the Defense Production Act of 1950 to alter the definitions of "prohibited technology" and "notifiable technology", and for other purposes.
Introduced June 2, 2026 by John Moolenaar · Last progress June 2, 2026
Makes biotechnology — including pharmaceutical drugs, biologics, drug discovery platforms, clinical R&D, and biologics manufacturing know‑how — an express category covered by the Defense Production Act outbound investment and technology control provisions. Directs Treasury to write rules within one year to define covered biotech transactions (emphasizing licensing, joint ventures, and equity investments to covered foreign persons, especially those tied to the People’s Republic of China), adds licensing of prohibited technology from covered foreign persons to the DPA list, and requires a DoD report within 60 days assessing whether U.S. capital flows into China’s biotech sector harm national security.